Listed by the USPTO as FRITCHMAN, REBECCA M
Tech Center 1700 • Art Units: 1645 1758 1759 1767 1777 1796 1797
This examiner grants 46% of resolved cases
FRITCHMAN, REBECCA M has resolved 665 cases in Tech Center 1700 and Art Unit 1645. The profile shows a 45.6% allowance rate and a median of 1473 days to allowance. The 35.4% interview lift is substantial, suggesting that purposeful examiner engagement may be particularly valuable when developing a path through substantive rejections.
The listed companies include Seer Inc., Nestlé S.A., and Regeneron Pharmaceuticals Inc. The representative firms are Casimir Jones, S.C., FOLEY & LARDNER LLP, and K&L Gates LLP-Nestec S.A. Counsel should combine interview preparation with careful amendment discipline and extended-timeline planning, given the profile’s allowance outcome and median pendency.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18027764 | MARKERS FOR DETECTING CARDIOVASCULAR DISEASE AND CARDIOVASCULAR DISEASE RISK | Final Rejection | The Regents of the University of Michigan |
| 17779104 | LABEL-FREE N-GLYCAN QUANTIFICATION METHODS | Final Rejection | Bristol-Myers Squibb Company |
| 18147094 | USE OF BIOMARKERS TO DETERMINE SUB-ACUTE TRAUMATIC BRAIN INJURY (TBI) IN A SUBJECT HAVING RECEIVED A HEAD COMPUTERIZED TOMOGRAPHY (CT) SCAN THAT IS NEGATIVE FOR A TBI OR NO HEAD CT SCAN | Non-Final OA | Abbott Laboratories |
| 18604429 | METABOLOMIC ANALYSIS | Non-Final OA | Genentech, Inc. |
| 17633917 | BIOMARKERS FOR NEURODEGENERATIVE DISORDERS | Non-Final OA | The Johns Hopkins University |
| 17435471 | HEMOLYSIS DETECTION BLOOD TESTING DEVICE | Non-Final OA | Siemens Healthcare Diagnostics Inc. |
| 18696187 | METHOD FOR DETECTING AND/OR QUANTIFYING MOOD DISORDER AND/OR IMPROVEMENTS OF THE MOOD DISORDER STATUS USING TRIGONELLINE AS BIOMARKER AND IMPROVED METHODS AND COMPOSITIONS THEREOF | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18559869 | METHOD FOR DETERMINING PERSONALIZED OMEGA-3 DOSE | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 18718434 | METHOD FOR QUANTIFYING CARBON IN CARBIDES | Non-Final OA | JFE STEEL CORPORATION |
| 18221934 | ISOELECTRIC FOCUSING-BASED ENRICHMENT OF CHARGE VARIANT SPECIES | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18286403 | Sample Conveying Device, Sample Analysis System, and Sample Pretreatment System | Final Rejection | Hitachi High-Tech Corporation |
| 17880676 | TARGET MATERIAL IDENTIFICATION METHOD | Final Rejection | Taiwan Semiconductor Manufacturing Company, Ltd. |
| 17436218 | IN VIVO REVERSIBILITY OF HIGH MOLECULAR WEIGHT SPECIES | Non-Final OA | AMGEN INC. |
| 18579203 | COMPOSITION CONTAINING TARC, DILUENT, METHOD FOR REDUCING TARC CARRYOVER, ADSORPTION INHIBITOR, AND CONTINUOUS ANALYSIS METHOD | Non-Final OA | SEKISUI MEDICAL CO., LTD. |
| 18277424 | IMMUNOLOGICAL ANALYSIS METHOD FOR TYPE-I COLLAGEN C-TERMINAL TELOPEPTIDE | Non-Final OA | SEKISUI MEDICAL CO., LTD. |
| 18014901 | GUIDING BLOOD PRODUCT ADMINISTRATION TO MITIGATE BLEEDING RISK | Non-Final OA | CHILDREN'S MEDICAL CENTER CORPORATION |
| 18028324 | FERRITIN MEASURING REAGENT | Final Rejection | Denka Company Limited |
| 16978959 | DETECTION OF ALZHEIMER'S DISEASE (AD), FRONTOTEMPORAL LOBAR DEGENERATION (FTLD), AMYOTROPHIC LATERAL SCHLEROSIS (ALS), PARKINSON'S DISEASE (PD), AND DEMENTIA WITH LEWY BODIES (DLB) INDICATED BY PHOSPHORYLATION OF MARCKS | Final Rejection | DENKA COMPANY LIMITED |
| 17599466 | GAS ADSORBENT, GAS ADSORBING DEVICE, AND GAS SENSOR | Final Rejection | PANASONIC HOUSING SOLUTIONS CO., LTD. |
| 18639371 | ALKENE DETECTION OF OZONE | Non-Final OA | Hach Company |
| 18014872 | METHOD FOR EVALUATING THE METABOLIC ACTIVITY OF A NON-CANCER CELL | Final Rejection | UNIVERSITA' DEGLI STUDI DI UDINE |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy45.6% of resolved applications examined by Rebecca M Fritchman were allowed (665 resolved cases), compared with 49.5% across Art Unit 1645 over the last five years.
This examiner's interview lift is +35.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Rebecca M Fritchman took 1,473 days on average from filing to allowance.
Rebecca M Fritchman examines applications in Art Unit 1645 in Tech Center 1700 (Chemistry & Materials).
